Results 11 to 20 of about 6,753 (182)

A Combination of Exercise and Therapy with Cabergoline Attenuate Disturbances of Pituitary-Gonadal Hormones in Hyperprolactinemic Male Patients [PDF]

open access: yesMontenegrin Journal of Sports Science and Medicine, 2020
This study aimed to investigate whether cabergoline therapy alone for six months or in combination with a light exercise programme for an additional three months can attenuate hyperprolactinemia in 13 male patients (range: 22 to 45 yrs.) through ...
Mohammad Fayiz AbuMoh'd   +3 more
doaj   +1 more source

Effect of Clarithromycin on the Pharmacokinetics of Cabergoline in Healthy Controls and in Patients With Parkinson’s Disease

open access: yesJournal of Pharmacological Sciences, 2006
.: Cabergoline is used in the treatment of Parkinson’s disease (PD). Clarithromycin is a potent inhibitor of CYP3A4 and P-glycoprotein and is often co-administered with cabergoline in usual clinical practice.
Akiko Nakatsuka   +7 more
doaj   +1 more source

Therapeutic activity of sarpogrelate and dopamine D2 receptor agonists on cardiovascular and renal systems in rats with alloxan-induced diabetes

open access: yesBMC Pharmacology and Toxicology, 2021
Background Dopamine D2 receptor agonists, bromocriptine and cabergoline, are notable medications in the treatment of Parkinsonism, hyperprolactinemia, and hyperglycemia.
Mohammed Ahmed Fouad Shalaby   +6 more
doaj   +1 more source

Diabetes mellitus remission in a cat with hyperadrenocorticism after cabergoline treatment

open access: yesJournal of Feline Medicine and Surgery Open Reports, 2021
Case summary A 7-year-old spayed female domestic shorthair cat weighing 5 kg was referred with polyuria, polydipsia, lethargy, abdominal distension and dermatologic abnormalities.
Diego D Miceli   +4 more
doaj   +1 more source

Early Prediction of Long-Term Response to Cabergoline in Patients with Macroprolactinomas [PDF]

open access: yesEndocrinology and Metabolism, 2014
BackgroundCabergoline is typically effective for treating prolactinomas; however, some patients display cabergoline resistance, and the early characteristics of these patients remain unclear.
Youngki Lee   +5 more
doaj   +1 more source

Cabergoline in the Treatment of Male Orgasmic Disorder—A Retrospective Pilot Analysis

open access: yesSexual Medicine, 2016
Introduction: Male orgasmic disorder is common, with few treatment options. Cabergoline is a dopamine agonist that acts centrally to normalize serum prolactin that could improve orgasmic dysfunction.
Adam B. Hollander, MD   +6 more
doaj   +1 more source

Dopamine and prolactin in migraine: Mechanisms and potential therapeutic targets. [PDF]

open access: yesJ Neuroendocrinol
Prolactin and dopamine modulate migraine‐relevant trigeminal pathways. Hyperprolactinemia is associated with migraine‐like headache, and preclinical studies show that prolactin enhances trigeminal excitability, particularly in females. Dopamine inhibits prolactin release and may also directly suppress trigeminovascular activity via D2 receptors in the ...
Hjelholt AJ   +3 more
europepmc   +2 more sources

Cabergoline therapy for Macroprolactinoma during pregnancy: A case report

open access: yesBMC Research Notes, 2012
Background We assessed the safety of Cabergoline therapy during pregnancy in a lady with hyperprolactinemia intolerant to Bromocriptine. Case presentation We report the case of a 31 year old lady who presented to us with uncontrolled hyperprolactinemia ...
Shahzad Hira   +2 more
doaj   +1 more source

Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma

open access: yesIndian Journal of Endocrinology and Metabolism, 2017
Background: Clinical relevance of association of cabergoline use for hyperprolactinemia and cardiac valvulopathy remains unclear. Objective: The aim of the study was to determine the prevalence of valvular heart abnormalities in patients taking ...
Shruti Khare   +6 more
doaj   +1 more source

Comparative efficacy and safety of generic (Bergolak) vs. brand cabergoline in the treatment of patients with prolactin-secreting tumors

open access: yesОжирение и метаболизм, 2015
Objective: To evaluate the effectiveness and safety of cabergoline drug Bergolak («Veropharm», Russia) in the treatment of patients with prolactin-secreting tumors.Materials and methods: The study included 14 patients (14 women, mean age 46±12) diagnosed
Galina Afanas'evna Melnichenko   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy